CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation

Blood

Volumn 113, Issue 7, 2009, Pages 1581-1588

  Bashey, Asad ^a,b   Medina, Bridget ^a   Corringham, Sue ^a   Pasek, Mildred ^b   Carrier, Ewa ^a   Vrooman, Linda ^b   Lowy, Israel ^c   Solomon, Scott R ^b   Morris, Lawrence E ^b   Holland, H Kent ^b   Mason, James R ^d   Alyea, Edwin P ^e   Soiffer, Robert J ^e   Ball, Edward D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NORTHSIDE HOSPITAL   (United States)

^c MEDAREX INC   (United States)

^d SCRIPPS CLINIC   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GEMCITABINE; INFLIXIMAB; IPILIMUMAB; MEPREDNISONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGITATION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ANXIETY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BLISTER; BLOOD LEVEL; BLURRED VISION; BONE PAIN; BREAST CANCER; BRONCHITIS; CANCER REGRESSION; CELLULITIS; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COLITIS; CONSTIPATION; COUGHING; CREATININE BLOOD LEVEL; DESQUAMATION; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRY SKIN; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEADACHE; HEART PALPITATION; HIP FRACTURE; HODGKIN DISEASE; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; HYPERNATREMIA; HYPERTHYROIDISM; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; HYPOTHYROIDISM; INFECTION; INSOMNIA; KIDNEY CARCINOMA; KNEE SWELLING; LEUKEMIA RELAPSE; LEUKOCYTOSIS; MALE; MANTLE CELL LYMPHOMA; MUCOSA INFLAMMATION; MULTICENTER STUDY; MUSCLE CRAMP; MYELOMA; NAUSEA; NEUTROPENIA; NIGHT SWEAT; PETECHIA; PHARYNGITIS; PHOTOPHOBIA; PNEUMONIA; POLYARTHRITIS; PRIORITY JOURNAL; PRURITUS; RASH; RECURRENT CANCER; REMISSION; RHEUMATOID ARTHRITIS; SENSORY NEUROPATHY; SHOULDER PAIN; SIDE EFFECT; SWELLING; TACHYCARDIA; THORAX PAIN; THROMBOCYTOPENIA; URINE RETENTION; VAGINITIS; VOMITING;

EID: 61849165013     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-07-168468     Document Type: Article

References (24)

1. Giralt SA, van Besien K. Treatment of relapse after allogeneic bone marrow transplantation. Cancer Treat Res. 1996;84:279-290.
2. Kahl C, Storer BE, Sandmaier BM, et al. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood. 2007;110: 2744-2748.
3. Salomon B, Bluestone JA. Complexities of CD28/ B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol. 2001;19:225-252.
4. Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv Immunol. 2006;90:297-339.
5. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3: 541-547.
6. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade [see comments]. Science. 1996;271:1734-1736.
7. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anticytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med. 1999;190:355-366.
8. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 2003;100:8372-8377.
9. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anticytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005;23: 6043-6053.
10. Maker AV, Phan GQ, Attia P, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol. 2005;12:1005-1016.
11. Sanderson K, Scotland R, Lee P, et al. Autoimmunity in a phase I trial of a fully human anticytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol. 2005;23:741-750.
12. Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006;24:2283-2289.
13. Cranmer LD, Hersh E. The role of the CTLA4 blockade in the treatment of malignant melanoma. Cancer Invest. 2007;25:613-631.
14. Downey SG, Klapper JA, Smith FO, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res. 2007;13:6681-6688.
15. Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res. 2007;13:1810-1815.
16. Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist. 2007;12:864-872.
17. Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007; 30:825-830.
18. O'Mahony D, Morris JC, Quinn C, et al. A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res. 2007;13:958-964.
19. Hodi FS, Butler M, Oble DA, et al. Immunologic and clinical effects of antibody blockade of cyto-toxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A. 2008;105:3005-3010.
20. Saenger YM, Wolchok JD. The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases. Cancer Immun. 2008;8:1.
21. Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Sharpe AH, Vallera DA. Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells. J Immunol. 1999;162:6368-6377.
22. Investigator Brochure for Ipilimumab. Wallingford, CT: Bristol-Myers Squibb Pharmaceutical Research Institute and Bloomsbury, NJ: Medarex, Inc; 2007.
23. Sprangers B, Fevery S, Van Wijmeersch B, De Somer L, Waer M, Billiau AD. Can graft-versus-leukemia reactivity be dissociated from graft-versus-host disease? Front Biosci. 2007;12:4568-4594.
24. Fevery S, Billiau AD, Sprangers B, et al. CTLA-4 blockade in murine bone marrow chimeras induces a host-derived antileukemic effect without graft-versus-host disease. Leukemia. 2007;21: 1451-1459.